BioAegis’ Patent Rights Extend to Applications for Inflammation Recombinant plasma gelsolin has been shown to be a biomarker of inflammation in a wide range of diseases and in particular in rheumatoid arthritis (RA). This abundant human plasma protein is expected to have utility in patients with RA, as well as other inflammatory diseases.
Plasma Gelsolin Could Hold the Key to the Body’s Ability to Localize Inflammation BOSTON MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(May 17, 2011) BioAegis Therapeutics, Inc. announced today that it has entered into an Exclusive Option Agreement with Brigham and Women’s Hospital for technology based on research of Dr. Thomas Stossel, Director, Translational Medicine at Brigham and …
LOCATION:
BioAegis Therapeutics
North Brunswick, NJ
MEDIA INQUIRIES:
Contact: Christine Lagana
clagana@bioaegistx.com
INVESTOR INQUIRIES:
Contact: Steven Cordovano
scordovano@bioaegistx.com
©2022 BioAegis® Therapeutics Inc. | Privacy Policy | Terms of Use